Neoadjuvant Intralesional Methotrexate for Infiltrating Squamous Cell Carcinoma of the Head: A Case Series of 19 Patients
Squamous cell carcinoma (SCC) of the head presents a significant challenge in achieving complete surgical excision while preserving function and aesthetics. Neoadjuvant intralesional methotrexate (MTX) has emerged as a potential strategy to reduce tumour burden preoperatively, facilitating more conservative surgical excisions. The results demonstrated significant lesion shrinkage, with a mean tumour size reduction of 68%, enabling less invasive surgical interventions.
Authors
- Giulia Briatico (ORCID: https://orcid.org/0000-0003-0421-3241)
- Camila Scharf (ORCID: https://orcid.org/0000-0003-3705-7310)
- Caterina Mariarosaria Giorgio (ORCID: https://orcid.org/0009-0003-2148-8914)
- Eugenia Veronica Di Brizzi (ORCID: https://orcid.org/0000-0002-0278-2443)
- Maria Maddalena Nicoletti (ORCID: https://orcid.org/0009-0000-8580-606X)
- Elvira Moscarella (ORCID: https://orcid.org/0000-0001-5160-8997)
- Gaetano Licata (ORCID: https://orcid.org/0000-0002-0834-1331)
- Gabriella Brancaccio (ORCID: https://orcid.org/0000-0001-8982-9410)
- Giuseppe Argenziano (ORCID: https://orcid.org/0000-0002-0834-1331)
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- Ospedale Sant Antonio (IT)
Publication Details
- Journal
- Australasian Journal of Dermatology
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1111/ajd.14529
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00